Improving treatment for pancreatic cancer by targeting a specific enzyme
Official title: Optimizing anti-wild-type IDH1 therapy in pancreatic cancer
Funded at Case Western Reserve University · NIH-11038046 · Data updated 2026-11-12
This study is looking at how a specific enzyme helps pancreatic cancer cells survive and is testing FDA-approved drugs that block this enzyme to see if they can make current treatments work better for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $661,060 |
| NIH project number | 5R01CA287672-02 |
| Project ID | NIH-11038046 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with pancreatic ductal adenocarcinoma, particularly those with wild-type IDH1 expression.
✕Less likely to help
Patients with other types of cancer or those whose tumors do not express wild-type IDH1 may not benefit from this research.
What this research studies
This research focuses on pancreatic ductal adenocarcinoma (PDAC), a highly lethal cancer with few effective treatments. The team is investigating how the enzyme wild-type IDH1 supports the survival of PDAC cells in a challenging environment. By using FDA-approved drugs that inhibit this enzyme, the researchers aim to enhance the effectiveness of existing therapies, potentially leading to better outcomes for patients. The study will explore various strategies, including pharmacological and dietary approaches, to optimize treatment and improve patient responses.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with pancreatic cancer.
How similar studies have gone: Previous research has shown promise in targeting wild-type IDH1 in pancreatic cancer, indicating that this approach could be effective.
Where this research is happening
-
Case Western Reserve University
Cleveland, United States Active
Researchers
- Principal investigator: Winter, Jordan M — Case Western Reserve University
- Study coordinator: Winter, Jordan M
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.